|View printer-friendly version|
Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
“In the first few months of 2019, we continued to make significant progress with our inarigivir clinical program, the development of our intravenously-administered Stimulator of Interferon Genes (STING) agonist SB 11285, and the lead novel antisense compound for HBV emerging from our R&D platform,” said
Mr. Driscoll continued, “We also revealed at EASL new preliminary data for the 400mg dose of inarigivir from a study in healthy volunteers. This study demonstrated uniform innate immune-activation with the inarigivir 400mg dose, yet without the systemic cytokine toxicity commonly associated with the use of interferon. Full data from this study will be reported at the Science of HBV Cure meeting in
Mr. Driscoll commented further, “I am also pleased to announce that our R&D team under Dr.
Recent Highlights and Business Developments
2019 First Quarter Financial Results
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of the company’s trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.